Los Angeles Capital Management LLC Sells 346,803 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Los Angeles Capital Management LLC decreased its stake in Royalty Pharma plc (NASDAQ:RPRX) by 89.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 40,894 shares of the biopharmaceutical company’s stock after selling 346,803 shares during the period. Los Angeles Capital Management LLC’s holdings in Royalty Pharma were worth $1,043,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of RPRX. Keene & Associates Inc. grew its stake in Royalty Pharma by 1.9% in the 4th quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company’s stock worth $495,000 after buying an additional 370 shares in the last quarter. Blue Trust Inc. raised its holdings in Royalty Pharma by 31.3% during the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 376 shares during the last quarter. Sanctuary Advisors LLC raised its holdings in Royalty Pharma by 0.9% during the 4th quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company’s stock valued at $1,068,000 after buying an additional 388 shares during the last quarter. Aurora Investment Counsel increased its position in Royalty Pharma by 1.0% during the 3rd quarter. Aurora Investment Counsel now owns 50,441 shares of the biopharmaceutical company’s stock valued at $1,427,000 after purchasing an additional 512 shares during the period. Finally, GAMMA Investing LLC increased its position in Royalty Pharma by 31.4% during the 4th quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 590 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Price Performance

Shares of RPRX stock opened at $33.64 on Friday. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $34.20. The firm has a market capitalization of $19.39 billion, a price-to-earnings ratio of 23.20, a PEG ratio of 2.31 and a beta of 0.49. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The stock’s 50-day simple moving average is $30.06 and its 200-day simple moving average is $28.18.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. As a group, equities analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be paid a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 2.62%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Friday, February 21st. Royalty Pharma’s dividend payout ratio is presently 60.69%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on RPRX. TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $41.60.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.